Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.

Oncotarget · 2016 · PMC4823044 · PMID 26573234

Europe PMC DOI

hedged sentences

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

of borderline significanceP = 0.058so close (0.05 < p ≤ 0.1)

No clinicopathologic features were significantly different between DLBCL patients with concurrent MYC/BCL6 rearrangements versus patients without MYC/BCL6 concurrent rearrangement, although larger tumor size was of borderline significance ( P = 0.058).

also in 2,624 other papers

showed a trendno p-value reported

These MYC / BCL6 DHL showed a trend toward higher MYC mRNA expression and a distinct gene expression profile compared to MYC / BCL2 DHL.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.